Published in Br J Cancer on November 16, 2010
Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 1.86
Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov (2013) 1.53
TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med (2013) 1.49
Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov (2013) 1.46
Death receptors as targets in cancer. Br J Pharmacol (2013) 1.24
Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth. J Immunol (2012) 0.97
The role of Bcl-xL in synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia on human colon cancer. Mol Cancer Res (2012) 0.96
RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells. J Invest Dermatol (2013) 0.95
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS One (2013) 0.91
Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening. Breast Cancer Res (2014) 0.88
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. Am J Cancer Res (2011) 0.88
Hyperthermia-enhanced TRAIL- and mapatumumab-induced apoptotic death is mediated through mitochondria in human colon cancer cells. J Cell Biochem (2012) 0.87
Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax. Cell Death Dis (2013) 0.86
Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp Biol Med (Maywood) (2015) 0.86
Sialic acid-binding lectin (leczyme) induces apoptosis to malignant mesothelioma and exerts synergistic antitumor effects with TRAIL. Int J Oncol (2013) 0.86
Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma (2014) 0.85
Antibody phage display libraries: contributions to oncology. Int J Mol Sci (2012) 0.85
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance. Am J Clin Exp Immunol (2013) 0.84
Evidence for two modes of synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia in human colon cancer cells. PLoS One (2013) 0.83
Hyperthermia enhances mapatumumab-induced apoptotic death through ubiquitin-mediated degradation of cellular FLIP(long) in human colon cancer cells. Cell Death Dis (2013) 0.82
Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther (2015) 0.80
Role of nanotechnology and gene delivery systems in TRAIL-based therapies. Ecancermedicalscience (2016) 0.79
Safety and tolerability of TRAIL receptor agonists in cancer treatment. Eur J Clin Pharmacol (2015) 0.79
Phage display-derived human antibodies in clinical development and therapy. MAbs (2016) 0.79
The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells. Biomed Res Int (2013) 0.77
Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism. Cell Death Dis (2014) 0.77
Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system. Int J Mol Sci (2014) 0.77
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat (2016) 0.76
Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL. Exp Cell Res (2015) 0.76
TNF related apoptosis-inducing ligand and its receptors in ocular tumors. Int J Ophthalmol (2011) 0.76
Sensitization of Melanoma Cells for Death Ligand TRAIL Is Based on Cell Cycle Arrest, ROS Production, and Activation of Proapoptotic Bcl-2 Proteins. J Invest Dermatol (2015) 0.76
Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator. Gene Ther (2015) 0.75
Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle. Sci Rep (2017) 0.75
The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis inducing ligand. J Biol Chem (2017) 0.75
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma. Cancer Med (2017) 0.75
Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. Oncol Rev (2017) 0.75
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer (2005) 1.58
Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin. J Urol (2007) 1.47
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.44
Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood (2001) 1.28
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer (2008) 1.27
Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol (2003) 1.17
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res (2009) 1.16
Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol (1997) 1.10
Trail receptors: targets for cancer therapy. Adv Exp Med Biol (2008) 1.04
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood (2006) 1.03
Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clin Cancer Res (2007) 0.99
Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res (2007) 0.95
On the thymus in the differentiation of "H-2 self-recognition" by T cells: evidence for dual recognition? J Exp Med (1978) 9.51
Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res (1977) 9.45
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res (2004) 9.18
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature (1985) 6.41
Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest (2001) 5.94
gltB gene and regulation of nitrogen metabolism by glutamine synthetase in Escherichia coli. J Bacteriol (1978) 5.59
Requirement for c-ras proteins during viral oncogene transformation. Nature (1986) 5.24
The Salmonella invasin SipB induces macrophage apoptosis by binding to caspase-1. Proc Natl Acad Sci U S A (1999) 5.17
The major histocompatibility complex of the mouse. Science (1979) 4.76
Studies on an acetate-fermenting strain of Methanosarcina. Appl Environ Microbiol (1978) 4.75
Serologically defined and lymphocyte-defined components of the major histocompatibility complex in the mouse. J Exp Med (1972) 4.59
Divergence time and population size in the lineage leading to modern humans. Theor Popul Biol (1995) 4.31
The lymphoreticular system in triggering virus plus self-specific cytotoxic T cells: evidence for T help. J Exp Med (1978) 4.27
STUDIES ON THE MECHANISM OF RECOVERY IN PNEUMOCOCCAL PNEUMONIA : IV. THE MECHANISM OF PHAGOCYTOSIS IN THE ABSENCE OF ANTIBODY. J Exp Med (1946) 4.20
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (1996) 4.07
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst (1999) 4.04
Genetic control of the immune response. Mapping of the Ir-1 locus. J Exp Med (1972) 3.96
The H-2 model for the major histocompatibility systems. Transplant Rev (1971) 3.82
List of congenic lines of mice. I. Lines with differences at alloantigen loci. Transplantation (1973) 3.73
Growth and methanogenesis by Methanosarcina strain 227 on acetate and methanol. Appl Environ Microbiol (1978) 3.70
Bracteomania, an inflorescence anomaly, is caused by the loss of function of the MADS-box gene squamosa in Antirrhinum majus. EMBO J (1992) 3.60
Cell-mediated lympholysis. Importance of serologically defined H-2 regions. J Exp Med (1973) 3.34
Serological identification of an Ir-region product. Science (1973) 3.32
Molecular cloning and characterization of the chicken gene homologous to the transforming gene of Rous sarcoma virus. Cell (1981) 3.26
A bacterial invasin induces macrophage apoptosis by binding directly to ICE. EMBO J (1996) 3.16
The traditional and a new version of the mouse H-2 complex. Nature (1981) 3.12
Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood (1999) 2.95
An unbiased signal-to-noise ratio measure for magnetic resonance images. Med Phys (1993) 2.83
Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet (2001) 2.79
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
MHC polymorphism pre-dating speciation. Nature (1988) 2.70
Therapy for acute otitis media. Preference of parents for oral or parenteral antibiotic. Arch Pediatr Adolesc Med (1996) 2.68
Biological and Immunological Properties of Encapsulated Strains of Staphylococcus aureus from Human Sources. Infect Immun (1970) 2.68
H-2 haplotypes, genes and antigens: second listing. II. The H-2 complex. Immunogenetics (1983) 2.62
Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr (1988) 2.62
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Origin of major histocompatibility complex polymorphism: the trans-species hypothesis. Hum Immunol (1987) 2.51
Cytotoxic T cells learn specificity for self H-2 during differentiation in the thymus. Nature (1978) 2.51
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50
The polymer mat: arrested rebound of a compressed polymer layer. Eur Phys J E Soft Matter (2002) 2.43
Phylogeny of Darwin's finches as revealed by mtDNA sequences. Proc Natl Acad Sci U S A (1999) 2.42
Genetic and immunological complexity of major histocompatibility regions. Science (1972) 2.40
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol (2000) 2.38
Heat labile opsonins to pneumococcus. II. Involvement of C3 and C5. J Exp Med (1969) 2.38
Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial. JPEN J Parenter Enteral Nutr (2000) 2.36
Polymorphism and balancing selection at major histocompatibility complex loci. Genetics (1992) 2.34
Directly measured second hand smoke exposure and asthma health outcomes. Thorax (2005) 2.32
Molecular characterisation of the Arabidopsis SBP-box genes. Gene (1999) 2.31
Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol (2009) 2.27
Heat labile opsonins to pneumococcus. I. Participation of complement. J Exp Med (1969) 2.24
Ir-genes in H-2 regulate generation of anti-viral cytotoxic T cells. Mapping to K or D and dominance of unresponsiveness. J Exp Med (1978) 2.24
Socio-economic disparities in preterm birth: causal pathways and mechanisms. Paediatr Perinat Epidemiol (2001) 2.19
Hair concentrations of nicotine and cotinine in women and their newborn infants. JAMA (1994) 2.18
Transformation of NIH/3T3 mouse cells by DNA of Rous sarcoma virus. Cell (1979) 2.17
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol (2007) 2.17
Evolution of the major histocompatibility complex. Crit Rev Immunol (1986) 2.16
A gain-of-function mutation in the sodium channel gene Scn2a results in seizures and behavioral abnormalities. Neuroscience (2001) 2.14
Essential role of insulin receptor substrate 1 in differentiation of brown adipocytes. Mol Cell Biol (2001) 2.14
Degradation of phenanthrene, fluorene and fluoranthene by pure bacterial cultures. Appl Microbiol Biotechnol (1990) 2.12
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol (2011) 2.12
H-2 mutations: their genetics and effect on immune functions. Adv Immunol (1978) 2.11
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol (2006) 2.10
Relation of Surface Phagocytosis to the Fibrinous Character of Acute Bacterial Exudates. Science (1949) 2.08
Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia (2007) 2.03
Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. J Clin Oncol (1993) 2.00
Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg (1999) 2.00
Nucleotide sequences of chimpanzee MHC class I alleles: evidence for trans-species mode of evolution. EMBO J (1988) 1.98
Serologic evidence for antigens controlled by the Ir region in mice. J Exp Med (1973) 1.94
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol (1991) 1.94
Intercellular Surface Phagocytosis. Science (1947) 1.92
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia (2011) 1.92
Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol (2006) 1.91
Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med (1990) 1.91
Graft-versus-host reactions across different regions of the H-2 complex of the mouse. J Exp Med (1973) 1.87
Isolation of Borrelia burgdorferi from the myocardium of a patient with longstanding cardiomyopathy. N Engl J Med (1990) 1.83
Mechanical properties of vascular smooth muscle cells in situ. Nature (1976) 1.82
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia (2010) 1.81
Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res (1998) 1.80
Fluidity of water confined to subnanometre films. Nature (2001) 1.80
Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem (1995) 1.80
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol (1995) 1.80
Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas. Leukemia (2007) 1.79
Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer. J Natl Cancer Inst (1995) 1.79
Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta (2001) 1.78
Quantitative evaluation of several partial Fourier reconstruction algorithms used in MRI. Magn Reson Med (1993) 1.76
Tissue distribution of I region-associated antigens in the mouse. J Immunol (1974) 1.76
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood (2001) 1.74
Production of anti-H-2 antibodies in thymectomized mice. Eur J Immunol (1974) 1.74
DNA archives and our nearest relative: the trichotomy problem revisited. Mol Phylogenet Evol (2000) 1.71
H-2 types of translocation stocks T(2;9)138Ca, T(9;13)-190Ca and an H-2 recombinant. Transplantation (1970) 1.71
Evidence supporting a two-gene model for the H-2 histocompatibility system of the mouse. J Exp Med (1972) 1.70
W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis. Development (1993) 1.70
Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ (1994) 1.68
Essential role of insulin receptor substrate-2 in insulin stimulation of Glut4 translocation and glucose uptake in brown adipocytes. J Biol Chem (2000) 1.67